Who is sponsoring NCT02912325?

NCT02912325 is sponsored by MDM S.p.A..

What drugs are being tested in NCT02912325?

Interventions in NCT02912325: Daily administration: 2 tablets FaseMETS a day.

What condition does NCT02912325 study?

NCT02912325 studies Metabolic Syndrome.

Is NCT02912325 still recruiting?

NCT02912325 is currently completed. Last updated 1 October 2019.

Last reviewed 2019-10-01 · How we verify

NCT02912325

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Non-Comparative Study to Assess the Efficacy and Safety of the New Food Supplement FaseMETS

Completed NA Last updated 1 October 2019

What this trial tests

NA trial testing Daily administration: 2 tablets FaseMETS a day in Metabolic Syndrome in 34 participants. Completed in 11 June 2018.

Timeline

9 May 2017

Primary endpoint
15 October 2017

11 June 2018

Quick facts

Lead sponsor	MDM S.p.A.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	34
Start date	9 May 2017
Primary completion	15 October 2017
Estimated completion	11 June 2018
Sites	2 locations across Romania

Drugs / interventions tested

Daily administration: 2 tablets FaseMETS a day

Conditions studied

Metabolic Syndrome — all drugs for Metabolic Syndrome →

Sponsor

MDM S.p.A. — full company profile →

Who can join

Adults 45 to 70, any sex, with Metabolic Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective is to evaluate the efficacy of FaseMETS for 6 consecutive months in lowering serum lipids and glucose in subjects with Metabolic Syndrome; The secondary objectives of the trial are: * to evaluate the potential benefit after 3 months of therapy (by an interim analysis) * to evaluate the safety of FaseMETS

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Metabolic Syndrome

Currently open trials in the same condition.

NCT07501858 — Assessing the Association Between H. Pylori Persistence and the Severity of Insulin Resistance in Patients With Metaboli · recruiting
NCT06857929 — "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition" · NA · recruiting
NCT07237750 — iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss · NA · recruiting
NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
NCT07383220 — Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02912325 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MDM S.p.A.
Last refreshed: 1 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02912325.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing